On June 24, 2025, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of shares of its common stock and pre-funded warrants at a price to the public of $12.00 per share. Wilson Sonsini Goodrich & Rosati advised Forte on the transaction.  The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about June 26, 2025, subject to satisfaction of customary closing conditions.

Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which include funding clinical and preclinical development of its FB-102 product candidate, a proprietary anti-CD122 monoclonal antibody therapeutic candidate.

The Wilson Sonsini team that advised Forte on the transaction includes:

Corporate
Dan Koeppen
Ben Capps 
Brandon Shaw
Dante Matera

Intellectual Property
Mike Hostetler 
Minyoung Shin

For more information, please see Forte’s news release.